About this item:

15 Views | 1 Download

Author Notes:

Shan Ping Yu, 101 Woodruff Circle, Suite 620, Emory University School of Medicine, Atlanta, GA 30322,Tel. 404-712-8678, spyu@emory.edu

Subjects:

Research Funding:

This work is supported by the NIH grants NS0458710 (SPY); R41NS073378 (SPY/TD); NS 057255 (LW); NS075338 (LW); NS062097 (LW); AHA Established Investigator Award (LW); and a Yerkes National Primate Center/NIH P51 grant (SPY).

This work was also supported by the NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.

CH was supported by NIH grant R25 NS065739.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Neurosciences
  • Neurosciences & Neurology
  • intracerebral hemorrhage
  • pharmacological hypothermia
  • PIH
  • neurotensin receptor
  • ABS-201
  • HPI-201
  • FOCAL CEREBRAL-ISCHEMIA
  • BLOOD-BRAIN-BARRIER
  • MILD HYPOTHERMIA
  • MODERATE HYPOTHERMIA
  • MATRIX METALLOPROTEINASES
  • THERAPEUTIC HYPOTHERMIA
  • SUBARACHNOID HEMORRHAGE
  • PROLONGED HYPOTHERMIA
  • FOREBRAIN ISCHEMIA
  • GENE-EXPRESSION

Acute and Delayed Protective Effects of Pharmacologically Induced Hypothermia in an Intracerebral Hemorrhage Stroke Model of Mice

Tools:

Journal Title:

Neuroscience

Volume:

Volume 252

Publisher:

, Pages 489-500

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Hemorrhagic stroke, including intracerebral hemorrhage (ICH), is a devastating subtype of stroke; yet, effective clinical treatment is very limited. Accumulating evidence has shown that mild to moderate hypothermia is a promising intervention for ischemic stroke and ICH. Current physical cooling methods, however, are less efficient and often impractical for acute ICH patients. The present investigation tested pharmacologically induced hypothermia (PIH) using the second-generation neurotensin receptor (NTR) agonist HPI-201 (formerly known as ABS-201) in an adult mouse model with ICH. Acute or delayed administrations of HPI-201 (2. mg/kg bolus injection followed by 2 injections of 1. mg/kg, i.p.) were initiated at 1 or 24. h after ICH. HPI-201 induced mild hypothermia within 30. min and body and brain temperatures were maintained at 32.7. ±. 0.4. °C for at least 6. h without causing observable shivering. With the 1-h delayed treatment, HPI-201-induced PIH significantly reduced ICH-induced cell death and brain edema compared to saline-treated ICH animals. When HPI-201-induced hypothermia was initiated 24. h after the onset of ICH, it still significantly attenuated brain edema, cell death and blood-brain barrier breakdown. HPI-201 significantly decreased the expression of matrix metallopeptidase-9 (MMP-9), reduced caspase-3 activation, and increased Bcl-2 expression in the ICH brain. Moreover, ICH mice received 1-h delayed HPI-201 treatment performed significantly better in the neurological behavior test 48. h after ICH. All together, these data suggest that systemic injection of HPI-201 is an effective hypothermic strategy that protects the brain from ICH injury with a wide therapeutic window. The protective effect of this PIH therapy is partially mediated through the alleviation of apoptosis and neurovascular damage. We suggest that pharmacological hypothermia using the newly developed neurotensin analogs is a promising therapeutic treatment for ICH.

Copyright information:

© 2013 IBRO.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote